Back to search

Boston University

Therapeutic development for VLCAD deficiency by small molecule screening

Abstract

dc:description.abstract

Objective: Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is a risk factor for various health defects, including rhabdomyolysis and metabolic myopathy. Metabolic myopathy and skeletal muscle defects can be seen in patients with mutations in the nuclear gene ACADVL that leads to a deficiency in the mitochondrial enzyme VLCAD. ACADVL is an important gene involved in the pathway for mitochondrial beta oxidation of fatty acids, specifically for very long-chain fatty acids. The lack of mitochondrial fatty acid oxidation due to VLCAD deficiencies leads to a decrease in energy production, which is detrimental to human health in times of need, especially during times of fasting and stress. Therefore, the goal of the research project is to develop methods to analyze the effects and symptoms of VLCAD deficiencies by modeling clinical stressors. To express clinically relevant phenotypes, we established a zebrafish model that incorporates exertional stress, enabling the development of a physiologically relevant parameter for therapeutic screening. By optimizing parameters for an exertion-based assay, we aim to develop a robust acadvl mutant zebrafish model that distinguishes phenotypes across genotypes and serves as a platform for screening therapeutics targeting mitochondrial dysfunction in VLCAD deficiency. From the experiments conducted, we were able to discover that increases within methylcellulose (MC) concentrations as well as increases within exposure time to MC led to significant decreases within the movement behavior/distances of zebrafish models. It was also determined that that increases in incubation temperature from 27-degrees (normal incubation temperature) to 32-degrees (elevated incubation temperature) also had an impact on significantly decreasing the movement behaviors/distances of acadvl zebrafish models. Although the experiments conducted have been proven promising in better understanding the disease phenotypes of those with mutations in the nuclear gene acadvl, further experiments will be needed to generate a more robust movement response in which can be further used in future drug screening.

Degree

thesis:*
Name thesis:degree_name
Master of Science
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Medical Sciences
Grantor
Boston University
Year dc:date.issued
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Zheng, Kenny
Advisors dc:contributor.advisor
  • Herscovitz, Haya
  • Gupta, Vandana
ORCID dc:identifier.orcid

Subjects

dc:subject × 1

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Handle dc:identifier.uri
https://hdl.handle.net/2144/53486

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
related terms
citation

Zheng, Kenny. Therapeutic development for VLCAD deficiency by small molecule screening. masters thesis, Boston University, 2026. https://hdl.handle.net/2144/53486